Evidence map›Paper›PMID 35800424›Full record

ArticleAsia Oceania journal of nuclear medicine & biology2022

Evaluation of [

Hemat Yaghoubi Mogadam, Mostafa Erfani, Mohammad Nikpassand, Masoud Mokhtary

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asia Oceania journal of nuclear medicine & biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution.

Hemat Yaghoubi MogadamDepartment of chemistry, Rasht Branch, Islamic Azad University, Rasht, Iran.
Mostafa ErfaniRadiation Applications Research School, Nuclear Science and Technology Research Institute, Tehran, Iran.
Mohammad NikpassandDepartment of chemistry, Rasht Branch, Islamic Azad University, Rasht, Iran.
Masoud MokhtaryDepartment of chemistry, Rasht Branch, Islamic Azad University, Rasht, Iran.
Nuclear Science and Technology Research Institute

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Clinical interest in metabolic imaging of cancer has been growing in recent years. The increase in protein metabolism of cancer cells is interesting target for metabolic tumor imaging, for which radiolabeled amino acids can be applied. The aim of this study was to evaluate a newly developed radiolabeled amino acid as an imaging protein metabolism in melanoma tumor. Methods: The radiolabeled tyrosine ([ Results: Radiolabeled tyrosine was attached in B16F10 melanoma cells and showed the cell binding capacity of 13.82±0.73%. In animal study, the accumulation of radiolabeled tyrosine was observed in B16F10 melanoma tumor (2.15±0.09 %ID/g) after 30 min post injection, so that the uptake ratio of tumor to muscle was about 5.11. Through scintigraphy process the melanoma tumor clearly visualized in mice at 30 min post injection. Conclusion: These data suggest that the novel radiotracer ([

Indexed as

Imaging agentLabeled amino acidMelanomaProtein metabolism

Identifiers

PMID35800424
PMCPMC9205849
OpenAlexW4285742334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.